U.S. SECURITIES AND
EXCHANGE COMMISSION
WASHINGTON, D.C.
FORM 12B-25
NOTIFICATION OF LATE FILING
SEC File Number 33-26787-D
CUSIP Number 989865 10 0
(Check One) [] Form 10-KSB [] Form 20-F [] Form 11-K
[X] Form 10-Q [] Form N-SAR
For Period Ended March 31, 2006
-----------------
[ ] Transition Report on Form 10-K
[ ] Transition Report on Form 20-F
[ ] Transition Report on Form 11-K
[ ] Transition Report on Form 10-Q
[ ] Transition Report on Form N-SAR
For the Transition Period Ended ___________
[Read Instruction (on back page) Before Preparing Form. Please Print or Type ]
Nothing in this form shall be construed to imply that the Commission
has verified any information contained herein.
If the notification relates to a portion of the filing checked above, identify
the Item(s) to which the notification relates: Not Applicable
PART I -- REGISTRANT INFORMATION
Zynex Medical Holdings, Inc
- --------------------------------------------------------------------------------
Full Name of Registrant
Fox River Holdings Inc.
- --------------------------------------------------------------------------------
Former Name if Applicable
8100 Southpark Way, Suite A-9
- --------------------------------------------------------------------------------
Addresses of Principal Executive Office
Littleton, CO 80120
- --------------------------------------------------------------------------------
City, State and Zip Code
PART II -- RULES 12B-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or expense
and the registrant seeks relief pursuant to Rule 12b-25(b), the following should
be completed. (Check box if appropriate) [X]
(a) The reasons described in reasonable detail in Part III of
- ---- this form could not be eliminated without unreasonable
effort or expense;
X
- ---- (b) The subject annual report, semi-annual report, transition
report on Form 10-K, Form 20-F, 11-K or Form N-SAR, or
portion thereof, will be filed on or before the fifteenth
calendar day following the prescribed due date; or the
subject quarterly report of transition report on Form 10-Q,
or portion thereof will be filed on or before the fifth
calendar day following the prescribed due date; and
- ---- (c) The accountant's statement or other exhibit required by Rule
12b-25(c) has been attached if applicable.
2
PART III -- NARRATIVE
State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q,
N-SAR or the transition report or portion thereof, could not be filed in the
prescribed period.
Zynex Medical Holdings, Inc. (the "Company") and its accountants need
additional time to finalize and analyze its financial statements and prepare
Management's Discussion and Analysis of Financial Condition and Results of
Operations.
PART IV -- OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to this
notification:
Thomas Sandgaard (800) 495-6670
--------------------------- ------------ ------------------
(Name) Area Code Telephone Number
(2) Have all other periodic reports required under Section 13 or 15(d) of the
Securities Exchange Act of 1934 or Section 30 of the Investment Company Act
of 1940 during the preceding 12 months or for such shorter period that the
registrant was required to file such report(s) been filed? If the answer is
no, identify report(s). Yes [X] No [ ]
(3) Is it anticipated that any significant change in results of operations from
the corresponding period for the last fiscal year will be reflected by the
earnings statements to be included in the subject report of portion
thereof? Yes [ ] No [ X ]
If so, attach an explanation of the anticipated change, both
narratively and quantatively, and, if appropriate, state the reasons
why a reasonable estimate of the results cannot be made.
Zynex Medical Holdings, Inc.
------------------------------------------
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the undersigned
hereunto duly authorized.
Date: May 15, 2006 By: /s/ Thomas Sandgaard
------------------ ---------------------------
Thomas Sandgaard
Chief Executive Officer and
Chief Financial Officer
3